23 completed, 11 unknown, 6 withdrawn, 5 not yet recruiting. 14 Not applicable, 14 Phase 2, 9 Phase 1, 6 Phase 3, 4 Phase 4.
Follow Erythema Multiforme: new trials by email Literature Review of Erythema Multiforme trials Research Report on Erythema Multiforme
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Withdrawn | Massachusetts General Hospital | 2030-01-01 | 2026-01-16 | ||
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| Comparison of Segmental Body Composition Characteristics in Lipedema and Obesity Bioelectrical Impedance Analysis, Numeric Rating Scale, Lower Extremity Functional Scale - Lipedema, Obesity | Recruiting | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | 200 | 2026-09-20 | 2026-10-16 | |
| Investigation of Systemic Inflammation Markers in Lipedema Clinical parameters, Laboratory parameters - Lipedema, Inflamation | Completed | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | 192 | 2026-06-01 | 2026-08-26 | |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| Using LUminoMark vs Coventional Practice for Targeted Axillary Surgery Targeting of axillary lymph nodes using LuminoMark, Targeting of axillary lymph nodes using conventional method - Breast Cancer, Axillary Lymph Nodes | Not applicable | Not yet recruiting | Kyungpook National University Chilgok Hospital | 330 | 2025-05-01 | 2025-03-30 |
| Severe Erythema Multiforme - CORTICO Prednisone 20 Mg, Oral Placebo, Methylprednisolone 120 Mg - Erythema Multiforme | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2024-05-01 | 2024-02-20 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis Abrocitinib, Tofacitinib - Toxic Epidermal Necrolysis | Early Phase 1 | Unknown | Peng Zhang | 30 | 2023-07-05 | 2023-11-28 |
| NATIENS: Optimal Management and Mechanisms of SJS/TEN Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4 - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Phase 3 | Completed | Vanderbilt University Medical Center | 2 | 2023-03-21 | 2025-12-17 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN Tofacitinib - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Not applicable | Completed | Chang Gung Memorial Hospital | 20 | 2022-08-01 | 2025-09-16 |
| Severe Bullous Drug Eruption and Filgrastim Filgrastim, Placebo - Rare Diseases, Toxic Epidermal Necrolyses | Phase 2 / Phase 3 | Unknown | Hospices Civils de Lyon | 42 | 2022-05-13 | 2024-05-08 |
| Apremilast for Erythema Multiforme Apremilast - Erythema Multiforme | Phase 2 | Completed | Robert Micheletti | 6 | 2022-01-13 | 2026-06-03 |
| Comparison of the Effect of Preemptive and Post-operative Erector Spina Plane Block on Intraoperative Opioid Consumption and Postoperative Analgesia in Patients Who Will Undergo Elective Thoracotomy Surgery, Guided by the Nociception Level Index (NoL) Erector Spina Plan Block - Erector Spina Plan Block, Preemptive Analgesia | Not applicable | Completed | Ankara University | 52 | 2022-01-01 | 2023-07-13 |
| Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Maskin Probe - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Not applicable | Unknown | Massachusetts Eye and Ear Infirmary | 30 | 2021-12-01 | 2021-12-06 |
| Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study Stevens-Johnson Syndrome, Drug Reaction With Eosinophilia and Systemic Symptom | Completed | Chulalongkorn University | 120 | 2021-05-30 | 2024-02-16 | |
| Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study) SARS-CoV-2 Infection, COVID-19 | Completed | University of Washington | 155 | 2020-12-10 | 2021-12-15 |
Showing 20 of 54. Sign in to see all of them.
Stevens-Johnson Syndrome (40) · Dry Eye Syndromes (5) · Pemphigoid, Benign Mucous Membrane (5) · Drug-Related Side Effects and Adverse Reactions (4) · Aniridia (2) · Autoimmune Diseases (2) · Burns, Chemical (2) · COVID-19 (2) · Coronavirus Infections (2) · Drug Eruptions (2) · Drug Hypersensitivity (2) · Drug Hypersensitivity Syndrome (2) · Graft vs Host Disease (2) · Limbal Stem Cell Deficiency (2)
Skin Diseases (54) · Skin Diseases, Vesiculobullous (54) · Skin and Connective Tissue Diseases (54) · Erythema (53) · Mouth Diseases (42) · Stomatognathic Diseases (42) · Hypersensitivity (41) · Immune System Diseases (41) · Stomatitis (41) · Chemically-Induced Disorders (40) · Dermatitis (40) · Hypersensitivity, Delayed (40) · Drug Eruptions (38) · Drug Hypersensitivity (38)
Infliximab (3) · Filgrastim (2) · tofacitinib (2) · Adalimumab (1) · Allopurinol (1) · Angioplasty, Balloon, Coronary (1) · Bevacizumab (1) · Capecitabine (1) · Clobetasol (1) · Cyclosporine (1) · Etanercept (1) · Febuxostat (1) · Fibroblast Growth Factor 7 (1) · Histocompatibility Testing (1) · Immunoglobulins, Intravenous (1)
Assistance Publique - Hôpitaux de Paris (3) · Massachusetts Eye and Ear Infirmary (3) · Chulalongkorn University (2) · Hospices Civils de Lyon (2) · Mahidol University (2) · Massachusetts General Hospital (2) · Seoul National University Hospital (2) · Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey (2) · Allenmore Hospital (1) · Ananias Diokno (1) · Ankara University (1) · Austrian Breast & Colorectal Cancer Study Group (1) · Brett King (1) · Centre Hospitalier Universitaire Vaudois (1) · Chang Gung Memorial Hospital (1)
United States (16) · China (4) · France (4) · Thailand (4) · Brazil (3) · Turkey (Türkiye) (3) · Belgium (2) · Pakistan (2) · South Korea (2) · Taiwan (2) · Austria (1) · Canada (1) · Germany (1) · Japan (1) · Russia (1)
James Chodosh, MD, MPH (2) · Pinnita Prabhasawat, MD (2) · Alexander de Vries, MD (1) · Ananias Diokno, MD (1) · Arturo Saavedra, MD, PhD (1) · Candy Estevez, M.Sc (1) · Carina Koppen, MD, PhD (1) · Chun Bing Chen (1) · Claes H Dohlman, MD, PhD (1) · Colleen Doherty, PhD(c),RN (1) · David Lechich, RN (1) · Dawn Fox, RN (1) · Dee Harris, BS,RRT,RPFT (1) · Dietmar Oefner, MD, MSc (1) · Donald T Tan, FRCS (1)
PMID 12558848, PMID 15161841, PMID 15287367, PMID 26297574, PMID 27106261, PMID 28476287, PMID 29478292, PMID 29569311, PMID 29800753, PMID 30346532, PMID 34734507, PMID 37086614, PMID 37678574
3UM1AI068614-14S1 (1), R01AG038673 (1)